1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow lanabecestat: new trials by email Literature Review of lanabecestat trials Research Report on lanabecestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Lanabecestat, Placebo - Alzheimer´s Disease | Phase 2 / Phase 3 | Terminated | AstraZeneca | 2218 | 2014-09-30 | 2019-12-03 |
Alzheimer Disease (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Tauopathies (1)
AstraZeneca (1)
Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Poland (1) · Puerto Rico (1) · Romania (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 27767991, PMID 31764959, PMID 33049114, PMID 40603145
2014 (1)